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Abstract
 While “omics” studies have advanced our understanding ofImportance:
inflammatory skin diseases, metabolomics is mostly an unexplored field in
dermatology.
 We sought to elucidate the pathogenesis of psoriatic diseases byObjective:
determining the differences in metabolomic profiles among psoriasis patients
with or without psoriatic arthritis and healthy controls.
 We employed a global metabolomics approach to compare circulatingDesign:
metabolites from patients with psoriasis, psoriasis and psoriatic arthritis, and
healthy controls.
 Study participants were recruited from the general community andSetting:
from the Psoriasis Clinic at the University of California Davis in United States.
 We examined metabolomic profiles using blood serum samplesParticipants:
from 30 patients age and gender matched into three groups: 10 patients with
psoriasis, 10 patients with psoriasis and psoriatic arthritis and 10 control
participants.
 Metabolite levels were measuredMain outcome(s) and measures(s):
calculating the mean peak intensities from gas chromatography time-of-flight
mass spectrometry.
 Multivariate analyses of metabolomics profiles revealed altered serumResults:
metabolites among the study population. Compared to control patients,
psoriasis patients had a higher level of alpha ketoglutaric acid (Pso: 288 ± 88;
Control: 209 ± 69; p=0.03), a lower level of asparagine (Pso: 5460 ± 980;
Control: 7260 ± 2100; p=0.02), and a lower level of glutamine (Pso: 86000 ±
20000; Control: 111000 ± 27000; p=0.02). Compared to control patients,
patients with psoriasis and psoriatic arthritis had increased levels of glucuronic
acid (Pso + PsA: 638 ± 250; Control: 347 ± 61; p=0.001). Compared to patients
with psoriasis alone, patients with both psoriasis and psoriatic arthritis had a
decreased level of alpha ketoglutaric acid (Pso + PsA: 186 ± 80; Pso: 288 ± 88;
p=0.02) and an increased level of lignoceric acid (Pso + PsA: 442 ± 280; Pso:
214 ± 64; p=0.02).
 The metabolite differences help elucidate theConclusions and relevance:
pathogenesis of psoriasis and psoriatic arthritis and they may provide insights
for therapeutic development.
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Introduction
Psoriasis is a chronic, inflammatory skin disease associated with 
significant morbidity and mortality1. Approximately one-third of 
psoriasis patients develop psoriatic arthritis2,3. The exact mecha-
nisms underlying psoriasis remain under investigation. A com-
plex interplay between genetic and environmental factors initiates 
a cascade of events that lead to activation of dendritic cells4. The 
activated dendritic cells stimulate differentiation and migration of 
effector T cells (Th1 and Th17) to the skin. The subsequent release 
of inflammatory cytokines promotes further recruitment of immune 
cells, stimulates keratinocyte proliferation and sustains a state of 
chronic inflammation4.
Genomics, proteomics, and transcriptomics research has substantially 
contributed to the growing body of knowledge concerning psoriasis 
etiology. For example, genome-wide transcriptional analysis and 
association studies have identified new susceptibility loci that impli-
cate pathways in psoriasis pathogenesis which integrate epidermal 
barrier dysfunction with immune dysregulation5–7. A recent prot-
eomic analysis of psoriatic skin tissue identified 36 up-regulated pro-
teins associated with the regulation of cell death, defense response, 
inflammatory response, and reactive oxygen species8. However, the 
data beyond genomics and proteomics at the metabolic level can pro-
vide new insights into the cellular processes involved in psoriasis.
Metabolomics, the most recent addition to the “omics” fields, is the 
comprehensive study of all low molecular mass metabolites in the 
metabolome of an organism under a given set of conditions9. Exam-
ining the metabolic byproducts produced at the transcriptional and 
translational levels will yield clues to the cellular regulatory pro-
cesses and underlying molecular networks. Because metabolites are 
the end products and the most downstream representation of cellular 
processes, the study of an organism’s metabolome is most reflective 
of any observable phenotype9. Metabolomics analysis will enable 
researchers to gain valuable information regarding the physiology 
of a system by measuring the amplified output that results from 
genetic and environmental perturbations10. To date, metabolomics 
has not yet been applied to investigate the systemic mechanisms 
underlying psoriasis.
Because psoriasis is a multifactorial disease at the genomic, pro-
tein, and cellular levels, it is important to examine the end products 
of cellular processes in psoriasis and psoriatic arthritis. In this novel 
study, we employed a global metabolomics approach using gas 
chromatography time-of-flight mass spectrometry (GC-TOF-MS) 
to compare the serum metabolic profiles of patients with psoriasis, 
patients with psoriasis and psoriatic arthritis, and healthy controls. 
We then summarized our results within the context of existing lit-
erature to generate hypotheses for future targeted analysis. Integrat-
ing genomics, proteomics, transcriptomics and metabolomics data 
from all levels will add to our understanding of the physiological 
processes underlying this complex disease and will provide poten-
tial insights into its associated comorbidities.
Methods
Study design
In this study, we examined the metabolite profiles of psoriasis patients 
with and without psoriatic arthritis and healthy controls using GC-
TOF-MS. Blood serum samples were obtained from 30 patients: 
10 patients with psoriasis, 10 patients with both psoriasis and pso-
riatic arthritis, and 10 healthy control participants. Patient demo-
graphics and treatments are summarized in Table 1. Plaque psoriasis 
is the most common subtype of psoriasis, and the diagnosis made 
by dermatologists based on characteristic red, scaly patches and 
plaques on characteristic locations. The Psoriasis Area and Severity 
Index (PASI) is a validated and widely used outcomes instrument 
in clinical trials that measures psoriasis severity. Psoriatic arthri-
tis is an inflammatory arthritis that typically affects the peripheral 
joints but can also have axial manifestations, enthethitis, and dac-
tylitis. In approximately 70–80% of patients with psoriatic arthritis, 
psoriasis precedes the development of joint symptoms. This study 
was approved by the Institutional Review Board at University of 
California, Davis (Protocol 254745-11). The Declaration of Helsinki 
was followed and the study participants provided their written, 
informed consent.
Sample storage and preparation
Blood samples were collected from patients using a BD 5 ml double-
gel serum separator tube. After 30 minutes of coagulation, the sam-
ples were immediately centrifuged at 2000 rpm for 15 minutes to 
complete blood fractionation11. Thereafter, the sera were transferred 
to Eppendorf tubes, snap-frozen in liquid nitrogen for 60 s, and 
stored at -80°C until further processing.
GC-TOF
Samples were analyzed using a GC-TOF approach. The study 
design was entered into the MiniX database12. A Gerstel MPS2 
automatic liner exchange system (ALEX) was used to eliminate 
cross-contamination from sample matrix occurring between sam-
ple runs. 0.5 microliter of sample was injected at 50°C (ramped to 
250°C) in splitless mode with a 25 sec splitless time. An Agilent 
6890 gas chromatograph (Santa Clara, CA) was used with a 30 m 
long, 0.25 mm i.d. Rtx5Sil-MS column with 0.25 µm 5% diphenyl 
film; an additional 10 m integrated guard column was used (Restek, 
Bellefonte PA)13–15. Chromatography was performed at a constant 
flow of 1 ml/min, ramping the oven temperature from 50°C for to 
330°C over 22 min. Mass spectrometry used a Leco Pegasus IV 
time of flight mass (TOF) spectrometer with 280°C transfer line 
temperature, electron ionization at −70 V and an ion source tem-
perature of 250°C. Mass spectra were acquired from m/z 85–500 at 
17 spectra/sec and 1750 V detector voltage.
Result files were exported to our servers and further processed by 
our metabolomics BinBase database. All database entries in BinBase 
were matched against the Fiehn mass spectral library of 1,200 authen-
tic metabolite spectra using retention index and mass spectrum 
information or the NIST11 commercial library. Identified metabo-
lites were reported if present in at least 50% of the samples per study 
design group (as defined in the MiniX database); output results were 
exported to the BinBase database and filtered by multiple parameters 
to exclude noisy or inconsistent peaks15. Quantification was reported 
as peak height using the unique ion as default. Missing values were 
replaced using the raw data netCDF files from the quantification 
ion traces at the target retention times, subtracting local background 
noise12. Sample-wise metabolite intensities were normalized by the 
total signal for all annotated analytes. Daily quality controls and 
standard plasma obtained from NIST were used to monitor instru-
ment performance over the length of the data acquisition.
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Table 1. Patient demographics. This table describes demographics and clinical information on the patient cohort that contributed their 
samples to this metabolomics study. Patient demographics indicated for patients with psoriasis (Pso), and patients with psoriasis and 
psoriatic Arthritis (PsA): age, sex, Body Mass Index (BMI), Psoriasis Area and Severity Index (PASI), duration of condition (in years), and 
current treatment(s). Demographics of age and sex for control patients are also indicated.
Psoriasis patients Psoriasis and PsA patients Control patients
Age Sex BMI PASI Duration Pso (yrs) Current treatment(s) Age Sex BMI PASI
Duration 
Pso/PsA 
(yrs)
Current treatment(s) Age Sex
60s M 22.0 23.5 44
Acitretin 25mg qd, 
calcipotriene/ 
betamethasone 
dipropionate as 
needed, fluocinolone 
cream as needed
60s M 31.3 7.2 Pso: 22 PsA: 22
Adalimumab 40mg 
every other week, 
clobetasol ointment 
0.05% as needed, 
calcitriol as needed
60s M
30s M 25.8 14.8 11
Ustekinumab 45mg 
every 12 weeks, 
clobetasol cream 
0.05% as needed
30s M 37.1 21.4 Pso: 15 PsA: 12
Adalimumab 40mg 
every week, methotrexate 
10mg weekly, 
calcipotriene as 
needed, fluocinonide 
cream as needed
30s M
20s F 28.8 12.2 13
Betamethasone 
diproprionate/
calcipotriene 
combination every day
40s F 28.3 16.2 Pso: 1 PsA: 1
NSAIDs, Clobetasol 
ointment twice 
daily, triamcinolone 
as needed to the 
intertriginous areas
20s F
30s M 43.6 9.6 21 Triamcinolone 0.1% cream twice daily 20s M 34.9 6.9
Pso: 4 
PsA: 4
Adalimumab 40mg 
every other week, 
clobetasol cream 
0.05% as needed, 
calcipotriene twice 
daily, hydrocortisone 
2.5% cream as needed
30s M
50s M 28.4 9.6 17
Clobetasol ointment 
0.05% daily, 
calcipotriene daily, 
etanercept 50mg 
every week
50s M 26.3 2.6
Pso: 43 
PsA: 
unknown
Methotrexate 15mg 
weekly, clobetasol 
cream 0.05% as 
needed, phototherapy 
(UVB) twice weekly
50s M
40s M 34.5 8 12
Clobetasol 0.05% 
cream as needed, 
calcipotriene as 
needed
40s M 28.0 22.5 Pso: 35 PsA: 2
Etancercept 50mg 
weekly, betamethasone 
dipropionate cream 
as needed, coal tar as 
needed
50s M
50s F 23.0 6 45 triamcinolone cream 0.5% twice daily 50s F 29.2 6.8
Pso: 11 
PsA: 9
Etanercept 50mg every 
week, clobetasol 
ointment 0.05% as 
needed
60s F
50s F 28.3 5.2 4
Adalimumab 40mg 
every other week, 
halobetasol cream 
0.05% as needed
50s F 28.3 27.5 Pso: 6 PsA: 5
NSAIDs, methotrexate 
12.5mg every week, 
clobetasol ointment 
0.05% as needed, 
calcipotriene as needed
50s F
40s F 22.1 4.4 9 Clobetasol cream 0.05% as needed 40s F 29.3 11.9 Unknown NSAIDs as needed 40s F
60s F 32.6 3.2 7
Etanercept 50mg every 
week, clobetasol, 
calcipotriene/ 
betamethasone 
dipropionate as 
needed
70s F 32.2 9 Unknown
NSAIDs as needed, 
fluocinonide cream as 
needed
70s F
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Data analysis
Statistical analysis was implemented on log2 transformed metab-
olite values in R16. The significance levels (i.e. p-values) were 
adjusted for multiple hypothesis testing according to Benjamini and 
Hochberg17 at a false discovery rate (FDR) of 5%.
Orthogonal signal correction partial least squares discriminant 
analysis (O-PLS-DA)18 was carried in out in R16 using the Devium 
package (https://github.com/dgrapov/devium).
A biochemical and chemical similarity network19 was developed for 
all measured metabolites with KEGG20 and PubChem CIDs21 iden-
tifiers. Enzymatic interactions were determined based on product- 
precursor relationships defined in the KEGG RPAIR database. 
Molecules not directly participating in biochemical transforma-
tions, but sharing many structural properties, based on PubChem 
Substructure Fingerprints22, were connected at a threshold of 
Tanimoto similarity ≥ 0.7.
Results
Psoriasis patients compared to control participants
Analysis of the human sera samples using GC-TOF-MS yielded 
144 known metabolic structures and a total of 354 molecular fea-
tures (Dataset). When comparing the metabolite profiles of psoria-
sis patients and control patients, the key differences that reached 
univariate significance were characterized by an increase in alpha 
ketoglutaric acid (mean peak intensity ± std dev: Pso: 288±88; 
Control: 209±69; p=0.03), and decreases in asparagine (mean peak 
intensity ± std dev: Pso: 5460±980; Control: 7260±2100; p=0.02), 
glutamine (mean peak intensity ± std dev: Pso: 86000±20000; 
Control: 111000±27000; p=0.02), and beta-sitosterol (mean peak 
intensity ± std dev: Pso: 217±100; Control: 315±130; p=0.04) in 
psoriasis patients compared to control patients (Figure 1, Dataset). 
OPLS-DA showed that all models performed significantly better 
(Q2=0.42±0.1; RMSEP=0.37±0.1) than what is expected based on 
random chance (permuted: Q2=-0.51±0.7; RMSEP=0.68±0.1).
Patients with psoriasis and psoriatic arthritis compared to 
patients with psoriasis
Upon comparing the metabolite profiles of patients with both 
psoriasis and psoriatic arthritis to patients with skin-limited 
psoriasis, the top metabolite differences were characterized by 
a decrease in alpha ketoglutaric acid (mean peak intensity ± std 
dev: Pso+PsA: 186±80; Pso: 288±88; p=0.02), and increases in 
arabinose (mean peak intensity ± std dev: Pso+PsA: 624±460; 
Pso: 363±90; p=0.04), lignoceric acid (mean peak intensity ± std 
dev: Pso+PsA: 442±280; Pso: 214±64; p=0.02), phosphoric acid 
(mean peak intensity ± std dev: Pso+PsA: 20600±4300; Pso: 
17100±3300; p=0.05), and glycerol-3-galactoside (mean peak 
intensity ± std dev: Pso: 193±140; Pso+PsA: 367±190; p=0.02) 
in psoriasis patients with concomitant psoriatic arthritis compared 
to patients with psoriasis alone (Figure 2, Dataset). The OPLS-
DA results suggest that the developed model did not perform 
significantly better (Q2=0.66±0.2; RMSEP=0.54±0.1) than what 
is expected based on random chance (permuted: Q2=0.47±0.3; 
RMSEP=0.55±0.1).
Patients with psoriasis and psoriatic arthritis compared to 
control participants
Key metabolite differences between patients with both psoria-
sis and psoriatic arthritis and healthy controls are characterized 
by increases in phosphoric acid (mean peak intensity ± std dev: 
Pso+PsA: 20600±4300; Control: 16300±4000; p=0.02), glucuronic 
acid (mean peak intensity ± std dev: Pso+PsA: 638±250; Con-
trol: 347±61; p=0.001), arabitol (mean peak intensity ± std dev: 
Pso+PsA: 238±65; Control: 172±61; p=0.03), and arabinose (mean 
peak intensity ± std dev: Pso+PsA: 624±460; Control: 322±140; 
p=0.02) in patients with both psoriasis and psoriatic arthritis 
compared to healthy individuals (Figure 3, Dataset). OPLS-DA 
analysis suggested that the developed model performed better 
(Q2=0.86±0.1; RMSEP=0.50±0.05) than what is expected based on 
random chance (permuted: Q2=0.48±0.4; RMSEP=0.55±0.1) and 
displays weak predictive performance.
Dataset 1. Data of metabolite differences in psoriasis and 
psoriatic arthritis
http://dx.doi.org/10.5256/f1000research.4709.d37090
A detailed legend of the raw data for Figures 1–3 can be found in 
the text file provided.
Discussion
Psoriasis is widely recognized as a condition that is more than “skin 
deep”. The infiltration of inflammatory cells in psoriasis dermis and 
epidermis may be released into systemic circulation, contributing 
to chronic systemic inflammation23. To our knowledge, this is the 
first study that employs a metabolomics approach to analyze human 
serum and examine metabolite changes in circulation beyond the 
skin. The spectral results indicated differences in low molecular 
weight compounds that may help distinguish psoriasis patients from 
healthy controls, psoriasis patients from patients with both psoriasis 
and psoriatic arthritis, and psoriasis patients with psoriatic arthritis 
from healthy controls. Although our metabolomics analysis detected 
a variety of altered metabolite levels, many of which warrant investi-
gation, herein, we discuss the altered levels of the metabolites where 
the most relevant literature exists. We place our findings within 
the context of existing literature and explore their relationship to 
the immune-mediated and inflammatory nature of the disease.
Psoriasis patients compared to control participants
Glutamine. Glutamine, the most abundant free amino acid in the 
body, is essential for protein synthesis and cellular growth24. In this 
study, GC-TOF-MS analysis revealed a decrease in glutamine lev-
els in the sera of patients with psoriasis when compared to healthy 
controls. The alteration in glutamine levels may be due to higher 
rates of protein synthesis, glutamine consumption by immune cells, 
and/or differences in transglutaminase levels between patients with 
and without psoriasis.
Psoriasis is characterized by high rates of cellular proliferation, 
which increases the cellular demand of amino acids, notably glu-
tamine, to accommodate for the higher rate of protein synthesis. 
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patients compared to controls. To determine whether these data 
are due either to an increase in deamidation rate or to an impaired 
repair system in patients with psoriasis, they measured the intracel-
lular levels of S-adenosylmethionine (SAM) and S-adenosylhomo-
cysteine (SAH). D’Angelo et al. found that the transmethylation 
potential (SAM/SAH) was comparable in patients and controls, 
indicating a normal repair system in psoriasis patients. Therefore, 
the increase in methyl esterification is more likely to be attributed to 
increased protein instability at asparagine sites, which is responsi-
ble for asparagine degradation and IsoAsp accumulation in psoria-
sis patients. Of note, isoAsp residues may confer immunogenicity 
to previously ignored self-antigens and need to be further explored 
given the immune-mediated nature of psoriasis31.
Alpha ketoglutaric acid. Alpha ketoglutarate is an intermediate of 
the citric acid cycle involved in cellular metabolism. The increase in 
alpha ketoglutaric acid levels detected in serum of psoriasis patients 
may be due to enhanced alpha ketoglutarate synthesis. Alpha 
ketogluarate is synthesized from isocitrate through a process medi-
ated by isocitrate dehydrogenase. Enzymatic assays from previous 
studies have reported significantly increased enzymatic activities of 
isocitrate dehydrogenase in psoriasis patients34.
The increase in alpha ketoglutaric acid levels may be a contribut-
ing factor to the increase in cellular proliferation associated with 
psoriasis. Singh et al. (2013) and Vishnoi et al. (2013) found that 
the in vitro addition of alpha ketoglutarate greatly enhanced cel-
lular proliferation rates, cell survival, and metabolic activity. Alpha 
ketoglutarate functions as a scavenger for removing toxic metabo-
lites within cells, thereby enhancing cell viability. Additional stud-
ies support alpha ketoglutarate involvement in cellular proliferation 
through regulation of the mTOR-signaling pathway35. mTOR, 
a protein kinase responsible for cell proliferation, cell survival, 
and protein synthesis, is phosphorylated by alpha ketoglutarate35. 
Therefore, increased alpha ketoglutarate levels may also activate 
mTOR pathways and induce cellular hyperproliferation.
Altered alpha ketoglutaric acid levels may also play a role within 
the hyperactive immunogenic state of psoriasis, in which lym-
phocytes, macrophages, and neutrophils secrete the inflammatory 
cytokines TNF-α, IL-1, and IL-6. In cell cultures, alpha ketoglu-
tarate appears to enhance macrophage cytotoxicity by significantly 
increasing TNF-α and nitric oxide release36. Furthermore, TNF-α 
release from macrophages can activate collagen synthesis in der-
mal fibroblasts of psoriatic skin. Previous studies have observed 
that psoriasis is associated with increased collagen synthesis37–39. 
Collagen functions as an abundant connective tissue protein and 
provides structural integrity for the epidermis. During collagen 
synthesis, alpha ketoglutarate functions as a cofactor that activates 
Prolyl-4-Hydroxylase (P4H), an enzyme that mediates the post-
translational modification of pre-procollagen peptides essential for 
formation of the collagen triple helix. Increased enzymatic activity 
of P4H enhances collagen synthesis in psoriatic lesions. Moreover, 
alpha ketoglutarate increases the available pool of proline residues 
required for collagen synthesis. Transamination of alpha ketoglu-
tarate into glutamate, with subsequent conversion into proline, 
provides P4H with additional proline substrates to synthesize the 
hydroxyproline required in collagen formation37. Taken together, 
This increased demand for glutamine is analogous to alterations of 
glutamine levels reported in patients with cancer, a condition also 
characterized by increased cellular proliferation24,25. In addition, 
psoriasis is also characterized by a dysregulated immune system 
whereby the amount and activity of immune cells are enhanced4. 
The proliferation and functions of immune cells are highly depend-
ent upon glutamine. High rates of glutamine consumption exhibited 
by lymphocytes, macrophages, and neutrophils have been reported 
in numerous studies in vitro26,27. Specifically, glutamine consump-
tion enhances the production of many cytokines, and among 
them, tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), 
interleukin-1β (IL-1β), and interleukin-6 (IL-6), all of which play 
an important role in psoriasis innate immunity.
Another possible explanation for the observed decrease in glutamine 
levels may be related to the up-regulation and increased expression 
of keratinocyte tranglutaminase in psoriatic lesions28,29. Keratino-
cyte transglutaminase is an enzyme critical for cornified envelope 
formation and participates in epidermal differentiation. Trans-
glutaminase catalyzes the formation of the N-(γ-glutamyl)-lysine 
isopeptide bond using the amino acids glutamine and lysine. The 
inhibition of keratinocyte transglutaminase expression by retinoic 
acid may explain, in part, one of the beneficial effects of retinoid 
use to treat psoriasis.
Asparagine. Asparagine, a common non-essential amino acid, is 
the amide of aspartic acid and is easily hydrolyzed during the cell 
aging process30,31. The spectral results showed a decrease in aspara-
gine levels in the serum of psoriasis patients, which may result 
from spontaneous asparagine deamidation, a process enhanced 
by an oxidative microenvironment. Chronic oxidative stress has 
been reported in patients with psoriasis32. In asparagine deamida-
tion, a spontaneous post-biosynthetic modification, the asparagine 
residue undergoes nucleophilic attack and forms a succinimide 
ring intermediate. The succinimidyl residue is an unstable five-
membered ring that hydrolyzes to give a mixture of aspartyl and 
isoaspartyl forms30. The resulting isoaspartate residue (isoAsp) 
is formed through a beta linkage as opposed to the normal alpha 
conformation, and is favored 3:1 over the normal conformation 
at physiological conditions31. The presence of isoAsp residues in 
proteins has been shown to decrease protein function and can trig-
ger autoimmune responses31. However, a protein repair system that 
employs the enzyme L-isoAsp-(D-Asp)-O-methyltransferase (PIMT) 
has recently been identified. PIMT specifically targets the isoAsp 
residues and forms an unstable methyl ester (L-isoaspartyl methyl 
ester), which is rapidly converted back to the L-succinimidyl form. 
The L-succinimidyl residues are then hydrolyzed to the L-aspartyl 
form30. This repair system prevents the accumulation of damaged 
proteins.
The observed decrease in asparagine is consistent with the find-
ings from a study by D’Angelo et al. (2012), who examined the 
abnormal isoaspartyl residues in the erythrocyte membranes of pso-
riasis patients33. D’Angelo et al. found that L-isoAsp content was 
highly increased in the red blood cells (RBC) membrane proteins 
of psoriatic patients. By measuring methyl esterification through an 
in situ protein methylation approach, the investigators found that 
protein methyl esterification was increased by 1.5 fold in psoriatic 
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that they bind44. Of note, GAGs have been proposed to store as 
well as activate growth factors in the extracellular matrix and cell 
surface44,45. This suggests that GAGs potentially play a significant 
role in influencing cell proliferation, differentiation, tissue remod-
eling, and regulation of extracellular matrix composition45–49. The 
GAGs present in the extracellular matrix of these cells may induce 
keratinocyte hyperproliferation and decrease epidermal differentia-
tion in psoriasis.
Studies have shown elevated levels of GAGs, specifically chondroi-
tin sulfate and dermatan sulfate, in dermatologic and urine samples 
of patients with psoriasis. Chondroitin sulfate is a class of GAG 
that consists of a disaccharide backbone composed of alternating 
D-glucuronic acid and N-acetyl-D-galatosamine, whereas dermatan 
sulfate is synthesized from the epimerization of the glucuronic acid 
residues to iduronic acid at the polymer level50. Using antibody stain-
ing against chondroitin sulfate, Smetsers et al. (2004) found that the 
chondroitin sulfate was primarily expressed in the papillary dermis 
and the basal keratinocytes in normal skin samples, whereas there 
was a more diffuse staining extending into the reticular dermis in pso-
riatic skin samples51. In a study examining the localization of various 
GAGs on skin cells of normal and psoriatic skin, Saga et al. (1995) 
found that psoriatic epidermis exhibited increased chondroitin sulfate 
as well as dermatan sulfate, verified through digestion by enzymes 
specific to certain GAGs52. The researchers also noted a higher con-
centration of chondroitin sulfate and dermatan sulfate from the stratum 
basale to the lower stratum spinosum in psoriasis patients compared to 
patients with normal skin52. Moreover, Poulsen et al. (1983) reported 
that the concentration of GAGs increased by 28% and 62% in the 
dermal and urine samples, respectively, of psoriatic patients versus the 
healthy controls53. In another study, Poulsen et al. (1982) noted that 
the excretion of dermatan sulfate doubled to 104% (p < 0.01) and the 
excretion of chondroitin sulfate increased by 62% (p < 0.02) in psoria-
sis patients versus controls54. However, only the excretion of dermatan 
sulfate correlated with the fraction of body surface area involved in the 
psoriasis patients54. It has been suggested that the increased urinary 
excretion of GAGs indicates greater catabolism55.
In patients with psoriasis and psoriatic arthritis, chronic inflam-
mation often leads to irreversible joint destruction56. Hyaluronan 
is another class of GAG composed of a D-glucuronic acid and 
N-acetyl-D-galatosamine backbone57. As a major component of the 
extracellular matrix in the articular cartilage, the joint destruction 
and degradation of hyaluronan into smaller oligosaccharides and its 
main components may account for the increase in glucuronic acid 
levels detected in our study. Although literature is scarce regarding 
the levels of hyaluronan in psoriatic arthritis, studies have reported 
an increase in serum hyaluronan in patients with rheumatoid arthri-
tis when compared to healthy individuals58–61. Of note, hyaluronan 
has exhibited a diverse biological role with opposing dual func-
tions in the inflammatory process57. Fragments of hyaluronan have 
been reported to enhance the inflammatory and catabolic response 
through the modulation of Toll-like receptor 2 signaling pathways62. 
While the suppression of hyaluronan synthesis alleviates inflamma-
tory responses in some arthritic models, hyaluronan can act as an 
inflammatory activator as well as an inflammatory moderator63,64. 
Taken together, because glucuronic acid is a crucial backbone of 
higher concentrations of alpha ketoglutaric acid may contribute to 
the structural properties as well as the immune and inflammatory 
properties of psoriasis.
Patients with psoriasis and psoriatic arthritis compared to 
patients with psoriasis
Alpha ketoglutaric acid. As noted earlier, alpha ketoglutarate can 
act to facilitate collagen synthesis in psoriasis patients. Although 
psoriasis patients exhibit elevated alpha ketoglutarate levels com-
pared to controls, patients diagnosed with psoriasis and psoriatic 
arthritis had lower serum alpha ketoglutarate levels. This may be 
the result of a higher inflammatory burden experienced by these 
patients. Inflammatory cytokines, particularly interleukins and 
TNF-α, are up-regulated in the synovial fluid of psoriatic arthritis 
patients, further enhancing inflammatory joint destruction and peri-
articular bone loss40. Collagen functions as the primary structural 
component in cartilage, bones, and skin. Degradation of joint tissue 
in patients with psoriasis and psoriatic arthritis may significantly 
increase the demand for alpha ketoglutarate in an attempt to syn-
thesize new collagen. This increased consumption may account for 
the decreased alpha ketoglutarate levels in patients with psoriasis 
and psoriatic arthritis.
Lignoceric acid. Lignoceric acid, a saturated very long-chain fatty 
acid (VLCA), is a minor fatty acid component found in human 
tissues and the bloodstream. In this study, serum lignoceric acid 
levels were elevated in patients with psoriasis with both skin and 
joint involvement when compared to patients with skin-limited 
psoriasis. The levels of saturated VLCFA in erythrocytes, specifi-
cally lignoceric acid, have been used to evaluate atherogenicity in 
patients with metabolic syndrome41. Similarly, Matsumori et al. 
(2013) found higher levels of lignoceric acid in the erythrocytes 
of patients with metabolic syndrome when compared to healthy 
controls41. This increase significantly correlated with specific ath-
erogenic lipoprotein profiles and systemic inflammation in patients 
with metabolic syndrome41. A metabolic syndrome is characterized 
partly by insulin resistance resulting from chronically elevated lev-
els of plasma free fatty acids that, when released into liver and mus-
cle tissue, inhibit insulin secretion42. Epidemiologic studies have 
shown an increased prevalence of metabolic syndrome in patients 
with psoriatic arthritis compared to patients with psoriasis only43. 
As such, the increase in lignoceric acid levels is consistent with 
the notion that psoriasis patients afflicted with concomitant pso-
riatic arthritis may experience a greater inflammatory burden than 
patients with skin involvement alone.
Patients with psoriasis and psoriatic arthritis compared to 
control participants
Glucuronic acid. Glucuronic acid is one of the main subunits that 
comprise the backbone of glycosaminoglycans (GAGs). In the pre-
sent study, levels of glucuronic acid were increased in patients with 
psoriasis and psoriatic arthritis when compared to healthy controls, 
which corroborates the role of GAGs in relation to psoriasis. GAGs 
are complex, negatively-charged polysaccharides that bind with 
proteins to form proteoglycans. These structures are intimately 
involved in crucial components of cell signaling, cell adhesion 
and cell migration as they modulate the activity of the proteins 
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GAGs, these results are consistent with our findings of elevated glu-
curonic acid in psoriatic serum samples.
In this study, a global metabolomics approach allowed an unbiased 
analysis of the entire pool of low molecular weight metabolites. 
The metabolomics data generated using this approach must be inte-
grated with prior knowledge to identify specific metabolites for 
targeted analysis in future studies and to validate/confirm findings. 
Our study has several limitations. The small sample size may be 
associated with the inability to detect potential differences in certain 
metabolites. In this pilot study, while we captured PASI scores, pso-
riasis patients were allowed to maintain their usual treatment regi-
mens. The effect of different treatment agents on metabolite pertur-
bations could not be determined in this pilot study. Future studies 
with a larger patient cohort are necessary to confirm these findings.
To our knowledge, this is the first study to evaluate the comprehen-
sive metabolome of patients with psoriasis. Differences in the serum 
metabolites of psoriasis patients, psoriasis patients with psoriatic 
arthritis, and control patients were detected through GC-TOF-MS, 
and further studies with larger sample sizes are necessary to confirm 
our findings. The development of a well-characterized metabolomics 
profile for patients with psoriasis and psoriatic arthritis will contrib-
ute to understanding pathophysiology of psoriasis and its associ-
ated comorbidities. The metabolite differences between psoriasis 
patients and healthy individuals detected by global metabolomics 
analysis help elucidate the underlying mechanisms of psoriasis 
and provide the foundations for therapeutic development.
Data availability
F1000Research: Dataset 1. Data of metabolite differences in pso-
riasis and psoriatic arthritis, 10.5256/f1000research.4709.d3709065 
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